Korean J Urol.  2012 Nov;53(11):761-765.

Prognostic Value of Body Mass Index in Korean Patients with Castration-Resistant Prostate Cancer

• Park JM
• Nam JS
• Na W
• Oh JJ
• Lee S
• Hong SK
• Byun SS
• Lee SE

Abstract

PURPOSE
We investigated the correlation between body mass index (BMI) and the prognosis of castration-resistant prostate cancer (CRPC) in patients who received docetaxel treatment.
MATERIALS AND METHODS
A retrospective study was conducted of 55 patients who were diagnosed with CRPC and received docetaxel treatment between 2003 and 2009 at our institution. Patients with a normal or lower BMI (<23.0 kg/m2) were categorized as group I and patients with an overweight or greater BMI (> or =23.0 kg/m2) were categorized as group II. Clinicopathological features and survival rates were evaluated by using the Kaplan-Meier method and Cox proportional hazards models.
RESULTS
On the basis of BMI, 27 patients (49.1%) belonged to group I and 28 (50.9%) patients belonged to group II. Mean follow-up periods were 30 months and 34.2 months, respectively (p=0.381). There were no significant differences between the two groups in terms of age, prostate-specific antigen (PSA), Gleason score, Eastern Cooperative Oncology Group Performance Status, hemoglobin level, alkaline phosphatase level, distant metastasis, radiation treatments, or performance of radical prostatectomy (p>0.05). In the univariate analysis for predicting survival rates, BMI (p=0.005; hazard ratio [HR], 0.121), logPSA (p=0.044; HR, 2.878), and alkaline phosphatase level (p=0.039; HR, 8.582) were significant factors for prediction. In the multivariate analysis, BMI (p=0.005; HR, 0.55), logPSA (p=0.008; HR, 7.836), Gleason score (p=0.018; HR, 6.434), hemoglobin (p=0.006; HR, 0.096), alkaline phosphatase level (p=0.005; HR, 114.1), and metastasis to the internal organs (p=0.028; HR, 5.195) were significant factors for prediction.
CONCLUSIONS
Better effects on the cancer-specific survival rate were observed in cases with higher BMI.

Keyword

Cancer specific survival; Castration-resistant prostate cancer; Obesity

MeSH Terms

Alkaline Phosphatase
Body Mass Index
Follow-Up Studies
Hemoglobins
Humans
Multivariate Analysis
Neoplasm Grading
Neoplasm Metastasis
Obesity
Overweight
Prognosis
Prostate
Prostate-Specific Antigen
Prostatectomy
Prostatic Neoplasms
Retrospective Studies
Survival Rate
Taxoids
Alkaline Phosphatase
Hemoglobins
Prostate-Specific Antigen
Taxoids

Figure

• 

  FIG. 1 Kaplan-Meier survival curves demonstrating patients' cancer-specific survival for castration-resistant prostate cancer on the basis of body mass index. BMI, body mass index.

Reference

1. Oh SW. Obesity and metabolic syndrome in Korea. Diabetes Metab J. 2011. 35:561–566.

2. Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev. 2001. 10:345–353.

3. Chi BH, Chang IH. Prostate cancer: recent trends in Korea. Urol Int. 2010. 85:88–93.

4. Giovannucci E, Rimm EB, Liu Y, Leitzmann M, Wu K, Stampfer MJ, et al. Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst. 2003. 95:1240–1244.

5. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003. 348:1625–1638.

6. Snowdon DA, Phillips RL, Choi W. Diet, obesity, and risk of fatal prostate cancer. Am J Epidemiol. 1984. 120:244–250.

7. Amling CL, Blute ML, Lerner SE, Bergstralh EJ, Bostwick DG, Zincke H. Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice. Mayo Clin Proc. 1998. 73:401–406.

8. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011. 59:572–583.

9. Jee SH, Yun JE, Park EJ, Cho ER, Park IS, Sull JW, et al. Body mass index and cancer risk in Korean men and women. Int J Cancer. 2008. 123:1892–1896.

10. Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet. 2011. 378:815–825.

11. Lopez-Jimenez F, Cortes-Bergoderi M. Update: systemic diseases and the cardiovascular system (i): obesity and the heart. Rev Esp Cardiol. 2011. 64:140–149.

12. Cosin Aguilar J, Hernandiz Martinez A, Masramon Morell X, Aristegui Urrestarazu R, Aguilar Llopis A, Zamorano Gomez JL, et al. Overweight and obesity in hypertensive Spanish patients. The CORONARIA study. Med Clin (Barc). 2007. 129:641–645.

13. Zalesin KC, Franklin BA, Miller WM, Peterson ED, McCullough PA. Impact of obesity on cardiovascular disease. Endocrinol Metab Clin North Am. 2008. 37:663–684.

14. Magheli A, Rais-Bahrami S, Trock BJ, Humphreys EB, Partin AW, Han M, et al. Impact of body mass index on biochemical recurrence rates after radical prostatectomy: an analysis utilizing propensity score matching. Urology. 2008. 72:1246–1251.

15. Irani J, Lefebvre O, Murat F, Dahmani L, Dore B. Obesity in relation to prostate cancer risk: comparison with a population having benign prostatic hyperplasia. BJU Int. 2003. 91:482–484.

16. Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med. 2006. 355:763–778.

17. Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr, Amling CL, Elashoff D, et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol. 2004. 22:446–453.

18. Halabi S, Ou SS, Vogelzang NJ, Small EJ. Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer. Cancer. 2007. 110:1478–1484.

19. Strom SS, Kamat AM, Gruschkus SK, Gu Y, Wen S, Cheung MR, et al. Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer. Cancer. 2006. 107:631–639.

20. Lee SE, Lee WK, Jeong MS, Abdullajanov M, Kim DS, Park HZ, et al. Is body mass index associated with pathological outcomes after radical prostatectomy in Korean men? BJU Int. 2011. 107:1250–1255.

21. Platz EA, Leitzmann MF, Michaud DS, Willett WC, Giovannucci E. Interrelation of energy intake, body size, and physical activity with prostate cancer in a large prospective cohort study. Cancer Res. 2003. 63:8542–8548.

22. Freedland SJ, Aronson WJ. Obesity and prostate cancer. Urology. 2005. 65:433–439.

23. Frystyk J, Vestbo E, Skjaerbaek C, Mogensen CE, Orskov H. Free insulin-like growth factors in human obesity. Metabolism. 1995. 44:10 Suppl 4. 37–44.

24. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1998. 279:563–566.

25. Bub JD, Miyazaki T, Iwamoto Y. Adiponectin as a growth inhibitor in prostate cancer cells. Biochem Biophys Res Commun. 2006. 340:1158–1166.